HIGHLIGHTS
- who: Jonathan C. H. Chan and Michael C. Y. Chan from the Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T G , Canada have published the article: SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?, in the Journal: Medicina 2023, 59, 388. of /2023/
- what: The aim of this review is to provide a summarized update on the recent major clinical outcome trials involving diabetes, cardiovascular disease, and renal disease populations. This trial demonstrated that SGLT2i therapy can be started safely and effectively in patients even after an episode of decompensation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.